ATE276764T1 - Camptothecin arzneimittelkombinationen mit verringerten nebenwirkungen - Google Patents

Camptothecin arzneimittelkombinationen mit verringerten nebenwirkungen

Info

Publication number
ATE276764T1
ATE276764T1 AT95925476T AT95925476T ATE276764T1 AT E276764 T1 ATE276764 T1 AT E276764T1 AT 95925476 T AT95925476 T AT 95925476T AT 95925476 T AT95925476 T AT 95925476T AT E276764 T1 ATE276764 T1 AT E276764T1
Authority
AT
Austria
Prior art keywords
side effects
drugs
drug combinations
reduced side
agents
Prior art date
Application number
AT95925476T
Other languages
English (en)
Inventor
Mark J Ratain
Elora Gupta
Original Assignee
Arch Dev Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Dev Corp filed Critical Arch Dev Corp
Application granted granted Critical
Publication of ATE276764T1 publication Critical patent/ATE276764T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT95925476T 1994-07-05 1995-07-05 Camptothecin arzneimittelkombinationen mit verringerten nebenwirkungen ATE276764T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27127894A 1994-07-05 1994-07-05
US08/423,641 US5786344A (en) 1994-07-05 1995-04-17 Camptothecin drug combinations and methods with reduced side effects
PCT/US1995/008394 WO1996001127A1 (en) 1994-07-05 1995-07-05 Camptothecin drug combinations and medicaments with reduced side effects

Publications (1)

Publication Number Publication Date
ATE276764T1 true ATE276764T1 (de) 2004-10-15

Family

ID=26954799

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95925476T ATE276764T1 (de) 1994-07-05 1995-07-05 Camptothecin arzneimittelkombinationen mit verringerten nebenwirkungen

Country Status (8)

Country Link
US (1) US5786344A (de)
EP (1) EP0768895B1 (de)
JP (2) JPH10505579A (de)
AT (1) ATE276764T1 (de)
AU (1) AU2959595A (de)
CA (1) CA2194277A1 (de)
DE (1) DE69533551D1 (de)
WO (1) WO1996001127A1 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
AU741439B2 (en) * 1996-12-30 2001-11-29 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
WO1998037892A1 (en) * 1997-02-27 1998-09-03 Pharmacia & Upjohn Company Tamoxifen as a therapy to reduce irinotecan hydrochloride-induced diarrhea
US6114376A (en) * 1997-04-30 2000-09-05 Mcgill University Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells
AU9785698A (en) 1997-10-02 1999-04-27 Microcide Pharmaceuticals, Inc. Fungal efflux pump inhibitors
US6214821B1 (en) * 1998-03-05 2001-04-10 Washington State University Research Foundation Methods and composition for the inhibition of cancer cells
AU3192299A (en) * 1998-03-18 1999-10-11 Wake Forest University Improved implantable biomaterials, compositions and methods for their preparation and uses thereof
US6706691B1 (en) * 1998-07-15 2004-03-16 Board Of Regents, The University Of Texas System Immunosupportive drug sparing diet
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US6706759B1 (en) 1998-09-08 2004-03-16 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
US7816403B2 (en) * 1998-09-08 2010-10-19 University Of Utah Research Foundation Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same
US6548540B2 (en) * 1998-09-08 2003-04-15 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
US6589987B2 (en) 1998-09-08 2003-07-08 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using tetraethyl thiuram disulfide
US6395481B1 (en) 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter
US6709465B2 (en) 1999-03-18 2004-03-23 Fossa Medical, Inc. Radially expanding ureteral device
US7214229B2 (en) 1999-03-18 2007-05-08 Fossa Medical, Inc. Radially expanding stents
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
DE60030283T2 (de) * 1999-05-17 2007-09-20 Cancer Research Ventures Ltd. Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
US6734192B1 (en) * 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
US6191119B1 (en) * 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
US6159935A (en) * 1999-11-29 2000-12-12 Pharmacia & Upjohn Co. Method for preventing diarrhea
AU2001229478A1 (en) * 2000-01-18 2001-07-31 University Of Massachusetts Glutamine prevention of delayed-onset irinotecan-induced diarrhea
CN1218698C (zh) * 2000-03-02 2005-09-14 金相建 用于治疗和预防肝纤维化和肝硬化的药物组合物
US7078045B2 (en) * 2000-03-02 2006-07-18 Sang-Geon Kim Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis
WO2001066144A2 (en) * 2000-03-08 2001-09-13 Rhode Island Hospital, A Lifespan Partner Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
US6548488B2 (en) * 2000-03-17 2003-04-15 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
US20030195161A1 (en) * 2000-03-17 2003-10-16 Bissery Marie Christine Composition comprising camptothecin or a camptothecin derivative and a topoisomerase II inhibitor for the treatment of cancer
KR20030067935A (ko) * 2002-02-09 2003-08-19 김상건 올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물
EP1292309A4 (de) * 2000-04-07 2004-08-11 Sang Geon Kim Prophylaktische und therapeutische verwendung von oltipraz als mittel gegen fibrose und zirrhose der leber und pharmazeutische zusammenstellung die oltipraz enthält
JP2004515453A (ja) 2000-05-05 2004-05-27 ウィスコンシン・アルムナイ・リサーチ・ファウンデーション 癌を化学療法および放射線療法に付する間に細胞を保護するための組成物および方法
EP1486212A1 (de) * 2000-06-01 2004-12-15 Sloan-Kettering Institute For Cancer Research Kombination von einem mutanten Herpesvirus mit Irinotecan zur Behandlung von Krebs
US6399651B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
US7897559B2 (en) * 2000-06-29 2011-03-01 Parks L Dean Dermatological composition and kit containing avermectin compound for treating dermatological conditions
US6319945B1 (en) * 2000-06-29 2001-11-20 L. Dean Parks Method of treatment of seborrheic dermatitis
US6353029B1 (en) * 2000-08-24 2002-03-05 Bristol-Myers Squibb Company Storage stable tretinoin and 4-hydroxyanisole containing topical composition
US6624317B1 (en) * 2000-09-25 2003-09-23 The University Of North Carolina At Chapel Hill Taxoid conjugates as antimitotic and antitumor agents
WO2002056872A2 (en) * 2000-10-31 2002-07-25 Chemgenex Therapeutics, Inc. Antiproliferative colchicine compositions and uses thereof
US20050170015A1 (en) * 2000-10-31 2005-08-04 Brown Dennis M. Antiproliferative colchicine compositions and uses thereof
EP1355634B8 (de) 2000-11-09 2009-03-04 Neopharm, Inc. Sn-38-lipidkomplexe und verfahren zu ihrer verwendung
DK1347743T3 (da) * 2000-12-07 2006-07-03 Univ Utrecht Holding Bv Præparat til behandling af inflammatoriske lidelser
EP1352970B1 (de) * 2000-12-12 2010-06-02 Nagoya Industrial Science Research Institute Verfahren zur abschätzung des risikos der expression einer durch die verabreichung einer verbindung, die entweder per se durch ugt1a1 metabolisiert wird oder deren zwischenverbindung durch das enzym metabolisiert wird, hervorgerufenen unerwünschten arzneimittelwirkung
US20030099960A1 (en) * 2001-01-26 2003-05-29 The University Of Chicago Compositions and methods for optimizing UGT2B7 substrate dosings and for predicting UGT2B7 substrate toxicity
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
US7691872B2 (en) * 2001-03-20 2010-04-06 University Of Kentucky Research Foundation Methods and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
EP1432815A4 (de) * 2001-09-14 2006-02-22 Univ Duke Chinon-reduktase 2 und aldehyd-dehydrogenase als therapeutische zielmoleküle
EP1293205A1 (de) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproinsäure und deren Derivate zur Kombinationsbehandlung von Krebs beim Menschen und zur Behandlung von Tumor-Metastasen und minimaler Resterkrankung
US7199122B2 (en) * 2001-10-02 2007-04-03 Fox Chase Cancer Center Methods for inhibiting angiogenesis
US20030194421A1 (en) * 2001-12-28 2003-10-16 Angiotech Pharmaceuticals, Inc. Treatment of uveitis
US6977247B2 (en) * 2002-02-21 2005-12-20 Supergen, Inc. Sequential therapy comprising a 20(S)-camptothecin and a pyrimidine base analog
US6627614B1 (en) * 2002-06-05 2003-09-30 Super Gen, Inc. Sequential therapy comprising a 20(S)-camptothecin and an anthracycline
US20050152962A1 (en) * 2002-06-12 2005-07-14 Metselaar Josbert M. Composition for treatment of inflammatory disorders
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
WO2004035032A2 (en) * 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
EP1393720A1 (de) * 2002-08-27 2004-03-03 Universiteit Utrecht Vesikel enthaltend Corticosteroide zur Behandlung von Krebs
US20040157837A1 (en) * 2002-11-07 2004-08-12 Serbedzija George N. Combinations for the treatment of fungal infections
US20040203034A1 (en) * 2003-01-03 2004-10-14 The University Of Chicago Optimization of cancer treatment with irinotecan
US20040167165A1 (en) * 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associated with an Edg-7 receptor
WO2004066987A2 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
US6893668B2 (en) * 2003-03-31 2005-05-17 Council Of Scientific And Industrial Research Process for isolation of anticancer agent camptothecin from Nothapodytes foetida
US20040248915A1 (en) * 2003-04-25 2004-12-09 Jacques Jolivet Method for administration of troxacitabine
ES2308208T3 (es) * 2003-05-30 2008-12-01 University Of Chicago Metodos y composiciones para predecir la toxicidad del irinotecano.
WO2005085473A2 (en) * 2004-03-01 2005-09-15 University Of Chicago Polymorphisms in the epidermal growth factor receptor gene promoter
US20090247475A1 (en) * 2004-03-05 2009-10-01 The Regents Of The University Of California Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies
WO2005087952A1 (en) * 2004-03-05 2005-09-22 The Regents Of The University Of California Methods and compositions relating to the pharmacogenetics of abcc2, ugt1a1, and/or slc01b1 gene variants
WO2005089639A2 (en) * 2004-03-16 2005-09-29 Talarico M D Matthew T Method for vascular dysregulation
CA2569139A1 (en) * 2004-06-04 2005-12-22 Smithkline Beecham (Cork) Limited Lapatinib with letrozole for use in a treatment of breast cancer
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
WO2006093994A2 (en) * 2005-03-02 2006-09-08 New Century Pharmaceuticals Methods and compositions for increasing the safety and efficacy of albumin-binding drugs
US20060222627A1 (en) * 2005-03-30 2006-10-05 Andrew Carter Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue
CA2789262C (en) 2005-04-28 2016-10-04 Proteus Digital Health, Inc. Pharma-informatics system
EP1790343A1 (de) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
US20070259031A1 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
EP2063905B1 (de) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Behandlungen von lebererkrankungen durch verabreichung von konjugaten aus rezeptor-assoziierten proteinen
US20100111874A1 (en) * 2007-03-19 2010-05-06 University Of Medicine And Dentistry Of New Jresey Method of cancer detection and treatment
GB0811175D0 (en) * 2008-06-18 2008-07-23 Prendergast Patrick T Anti-tumour compositions and methods
TR201908314T4 (tr) 2009-02-20 2019-06-21 2 Bbb Medicines B V Glutatyon bazlı ilaç dağıtım sistemi.
KR101909711B1 (ko) 2009-05-06 2018-12-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2014022357A1 (en) * 2012-07-30 2014-02-06 Isis Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
US10369108B2 (en) 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
US10098813B2 (en) 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
IL261038B2 (en) 2016-02-09 2024-06-01 Sun Pharmaceutical Ind Ltd perfusion system
WO2020248824A1 (en) * 2019-06-14 2020-12-17 Hsu Wen Ming Method and pharmaceutical composition for prevention and treatment of a cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents

Also Published As

Publication number Publication date
JPH10505579A (ja) 1998-06-02
JP2006328087A (ja) 2006-12-07
EP0768895A1 (de) 1997-04-23
US5786344A (en) 1998-07-28
WO1996001127A1 (en) 1996-01-18
CA2194277A1 (en) 1996-01-18
DE69533551D1 (de) 2004-10-28
AU2959595A (en) 1996-01-25
EP0768895B1 (de) 2004-09-22

Similar Documents

Publication Publication Date Title
ATE276764T1 (de) Camptothecin arzneimittelkombinationen mit verringerten nebenwirkungen
WO2001080896A3 (en) Flavopiridol drug combinations and methods with reduced side effects
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
DE69635671D1 (de) Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
DE69709407D1 (de) Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen
DK0661987T3 (da) Morphogeninduceret leverregeneration
WO2001078783A3 (en) Compositions comprising natural agents for treatment of cancer
AU4258101A (en) Combination therapies with vascular damaging activity
NO20024076L (no) Sammensetning omfattende camptotecin og et pyrimidinderivat for behandling av cancer
SE9603725D0 (sv) New teatment
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
ATE226065T1 (de) Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung
WO2005042699A3 (en) Modified polypeptides with therapeutic activity and methods of use
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
AU5158000A (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
DE60134408D1 (de) Für akzessorische hiv proteine kodierende dna impfstoffe
WO2002012336A3 (en) TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE
MX2024014811A (es) Composiciones de menaquinol pegilado y metodos de tratamiento

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties